Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
复制标题
DOI：
10.1016/j.pcd.2011.09.002
复制
发表时间：
2012-04-01
影响因子：
2.9
通讯作者：
Lager, Ibe
中科院分区：
文献类型：
--
作者：
Lind, Marcus;Jendle, Johan;Lager, Ibe
目的：为了评估的影响，添加胰高血糖素样肽-1（GLP-1）类似物治疗胰岛素对糖化血红蛋白（HbA 1c），体重，胰岛素剂量，治疗满意度，和低血糖症的风险。方法：2型糖尿病患者接受胰岛素治疗GLP-1类似物在4个瑞典中心进行了研究。使用血糖仪和患者自我报告评估低血糖。采用糖尿病治疗满意度问卷（DTSQ）评价治疗满意度。结果：65例患者中，4例因低血糖而停药，无一例因低血糖而停药，无可疑严重不良事件。在平均持续治疗7.0个月的61例患者中，40例接受利拉鲁肽治疗，21例接受艾塞那肽治疗。HbA 1c从平均8.9%（82.4 mmol/mol）降至7.9%（71.9 mmol/mol）（p < 0.001），体重从111.1 kg降至104.0 kg（p
Aims: To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia.Methods: Type 2 diabetes patients with insulin therapy receiving a GLP-1 analogue at 4 Swedish centers were studied. Hypoglycemia was evaluated using glucometers and patient self-report. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was used to evaluate treatment satisfaction.Results: Among 65 patients studied, 4 discontinued therapy, none due to hypoglycemia, and there were no suspected severe adverse events. Among 61 patients who remained on therapy over a mean of 7.0 months, 40 were treated with liraglutide and 21 with exenatide. HbA1c decreased from a mean of 8.9% (82.4 mmol/mol) to 7.9% (71.9 mmol/mol) (p < 0.001), weight decreased from 111.1 kg to 104.0 kg (p